Head-to-head evidence
Tiotropium bromide vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT02172287 · Phase 3 · completed
This is a large, randomized, double-blind trial with both an active comparator and a placebo arm, using trough FEV1 lung function, the regulator-accepted physiological measure for COPD, as one of its primary endpoints. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Next expected readout: December 2026 · NCT07133880 (registry estimate)
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT00772538 · Phase 3 · completed
The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.
Next expected readout: January 2027 · NCT06679465 (registry estimate)
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tiotropium bromide's landscape · Umeclidinium's landscape